Head-to-head evidence
AGSAVI vs AJU-C52
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensin II receptor / Calcium channel / Thiazide-like diuretic · full Hypertension pipeline
AGSAVI
Developed by Ahn-Gook Pharmaceutical
NCT05503953 · Phase 3 · completed
The study was randomized, double-blind, and active-controlled, with 318 participants, and evaluated a clinical blood-pressure endpoint. Because the registry does not report whether the primary comparison was statistically significant, the findings cannot be classified as demonstrating a positive effect.
AJU-C52
Developed by AJU Pharm
NCT06416865 · Phase 3 · completed
This is a randomized, quadruple-blind, controlled study with an adequate sample size measuring a direct blood-pressure outcome, but no results have been posted yet, so the outcome is unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AGSAVI's landscape · AJU-C52's landscape